Form 8-K - Current report:
SEC Accession No. 0001140361-26-018716
Filing Date
2026-05-04
Accepted
2026-05-04 09:12:45
Documents
15
Period of Report
2026-05-04
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20072211_8k.htm   iXBRL 8-K 67994
2 EXHIBIT 10.5 ef20072211_ex10-5.htm EX-10.5 297159
3 EXHIBIT 99.1 ef20072211_ex99-1.htm EX-99.1 18816
7 image00004.jpg GRAPHIC 3584
8 image00005.jpg GRAPHIC 3379
  Complete submission text file 0001140361-26-018716.txt   580253

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA gyre-20260504.xsd EX-101.SCH 3859
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20260504_lab.xml EX-101.LAB 22691
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20260504_pre.xml EX-101.PRE 16548
19 EXTRACTED XBRL INSTANCE DOCUMENT ef20072211_8k_htm.xml XML 4366
Mailing Address 12770 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130 (858) 567-7770
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 26934897
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)